2016
DOI: 10.1093/infdis/jiw173
|View full text |Cite
|
Sign up to set email alerts
|

Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection

Abstract: IL-6 is a stronger predictor of fatal events than of CVD and non-AIDS-defining malignancies. Adjuvant antiinflammatory and antithrombotic therapies should be tested in HIV-infected individuals.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
85
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 98 publications
(87 citation statements)
references
References 48 publications
2
85
0
Order By: Relevance
“…This finding may underscore the complexities in cytokine signaling and suggest the need for different biomarkers as measures of inflammation to predict these outcomes. Cytokines, particularly IL-6 [31, 32], do predict clinical outcomes; for more subtle changes in pharmacology, other biomarkers of inflammation, such as soluble immune cell markers, cellular immune phenotypes, or kallistatin [33] may better predict changes that could influence drug toxicity and efficacy, and should be explored further.…”
Section: Discussionmentioning
confidence: 99%
“…This finding may underscore the complexities in cytokine signaling and suggest the need for different biomarkers as measures of inflammation to predict these outcomes. Cytokines, particularly IL-6 [31, 32], do predict clinical outcomes; for more subtle changes in pharmacology, other biomarkers of inflammation, such as soluble immune cell markers, cellular immune phenotypes, or kallistatin [33] may better predict changes that could influence drug toxicity and efficacy, and should be explored further.…”
Section: Discussionmentioning
confidence: 99%
“…Increases in many chronic diseases would be expected with prolonged life expectancy,6 but a key factor contributing to excess rates of non‐AIDS events among treated HIV+ patients includes persistent abnormalities in systemic inflammation and coagulation activity 7, 8, 9. Higher levels of biomarkers such as d ‐dimer and interleukin‐6 (IL‐6)8, 9, 10 among HIV+ patients have been shown to be positively associated with anemia,11 cancer,12 cardiovascular disease,10 type 2 diabetes,13 progression to AIDS,14 and composite non‐AIDS related clinical events and all‐cause mortality 7, 8, 15. However, a mechanistic basis for the connection between HIV‐associated alterations in coagulation activity and risk for a broad spectrum of non‐AIDS defining diseases has yet to be elucidated.…”
Section: Introductionmentioning
confidence: 99%
“…The question as to how combination antiretroviral therapy (cART) influences cancer risk has been debated since the beginning of the AIDS epidemics. During HIV infection, cancer risk seems to be determined by a complex interaction between prolonged life expectancy [1], traditional risk factors [11-12], pro-oncogenic viruses co-infection, potentially direct oncogenic effects of HIV [13-15], cART toxicity [16, ••17, •18] and activated inflammation and coagulation [19-23]. It is thus difficult to disentangle the direct effect of cART on cancer risk from other factors postulated to pay a role in carcinogenesis.…”
Section: Introductionmentioning
confidence: 99%
“…From our studies, PI-based regimens were linked to higher levels of IL-6 [70], a cytokine involved in all stages of cancer development [71]. Elevated plasma levels of IL-6 and other biomarkers of activated inflammation and coagulation were linked to future risk of both infection-related and infection-unrelated malignancies among HIV+ persons [19-21;23]. In one randomised trial, participants switching away from PI-based regimens experienced significant reductions in IL-6 levels when compared to participants continuously receiving PIs [72].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation